Endometrioid carcinoma associated with ovarian endometriosis: need for cautions during treatment

Although endometriosis could be associated with certain epithelial ovarian cancers and elevated serum cancer antigen (CA) 19-9 levels, it is difficult to diagnose endometriosis using this marker. We report an unusual case of endometriosis that evolved into endometrioid carcinoma in an asymptomatic 38-year-old woman with elevated CA 19-9 levels who presented to our clinic. Transvaginal ultrasound and computed tomography of the abdomen and pelvis revealed endometriosis of the right ovary. A laparoscopy was performed to evaluate for chocolate cysts. However, based on the postoperative pathological assessment, she was diagnosed with endometrioid carcinoma associated with endometriosis and was reoperated for surgical staging. This case indicates that sudden elevation of CA 19-9 level might be a sign of malignancy, small asymptomatic endometriosis should not be ignored, and incidental diagnosis of ovarian cancer should be carefully assessed by surgical staging.

Endometrioid carcinoma; Endometriosis; CA 19-9; Surgical staging

[1] Paik ES, Kim TJ, Choi CH, Kim BG, Bae DS, Lee JW. Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis. Journal of Gynecologic Oncology. 2018; 29: e18.

[2] Shafrir AL, Farland LV, Shah DK, Harris HR, Kvaskoff M, Zondervan K, et al. Risk for and consequences of endometriosis: a critical epidemiologic review. Best Practice & Research Clinical Obstetrics & Gynaecology. 2018; 51: 1–15.

[3] Saavalainen L, Lassus H, But A, Tiitinen A, Härkki P, Gissler M, et al. Risk of gynecologic cancer according to the type of endometriosis. Obstetrics & Gynecology. 2018; 131: 1095–1102.

[4] Lee SP, Sung I, Kim JH, Lee S, Park HS, Shim CS. Usefulness of carbohydrate antigen 19-9 test in healthy people and necessity of medical follow-up in individuals with elevated carbohydrate antigen 19-9 level. Korean Journal of Family Medicine. 2019; 40: 314–322.

[5] Nakagawa N, Koda H, Nitta N, Nakahara Y, Uno J, Hashimoto T, et al. Reactivity of CA 19-9 and CA 125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis. Acta Medicinae Okayama. 2015; 69: 227–235.

[6] Tomassetti C, Johnson NP, Petrozza J, Abrao MS, Einarsson JI, Horne AW, et al. An international terminology for endometriosis, 2021. Journal of Minimally Invasive Gynecology. 2021; 28: 1849–1859.

[7] Audebert A, Petousis S, Margioula-Siarkou C, Ravanos K, Prapas N, Prapas Y. Anatomic distribution of endometriosis: a reappraisal based on series of 1101 patients. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2018; 230: 36–40.

[8] Sampson JA. Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Archives of Surgery. 1925; 10: 1.

[9] Scott RB. Malignant changes in endometriosis. Obstetrics & Gynecology. 1953; 2: 283–289.

[10] Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al. ESHRE guideline: endometriosis. Human Reproduction Open. 2022; 2022: hoac009.

[11] Timmerman D, Planchamp F, Bourne T, Landolfo C, du Bois A, Chiva L, et al. ESGO/ISUOG/IOTA/ESGE consensus statement on preoperative diagnosis of ovarian tumors. Ultrasound in Obstetrics and Gynecology. 2021; 58: 148–168.

[12] Van Calster B, Van Hoorde K, Froyman W, Kaijser J, Wynants L, Landolfo C, et al. Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors. Facts, Views & Vision in ObGyn. 2015; 7: 32–41.

[13] Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Human Reproduction. 2013; 28: 1552–1568.

[14] Robinson KA, Menias CO, Chen L, Schiappacasse G, Shaaban AM, Caserta MP, et al. Understanding malignant transformation of endometriosis: imaging features with pathologic correlation. Abdominal Radiology. 2020; 45: 1762–1775.

[15] Magalhães JDS, Jammal MP, Crispim PCA, Murta EFC, Nomelini RS. Role of biomarkers CA-125, CA-15.3 and CA-19.9 in the distinction between endometriomas and ovarian neoplasms. Biomarkers. 2021; 26: 268–274.

[16] Chew KT, Zakaria IA, Abu MA, Ahmad MF, Hing EY, Abdul Ghani NA. Elevated serum CA 19-9 with adnexal mass: is it always an ovarian malignancy? Hormone Molecular Biology and Clinical Investigation. 2018; 34.

[17] Pandey D, Sharma R, Sharma S, Salhan S. Unusually high serum levels of CA 19-9 in an ovarian tumour: malignant or benign? Journal of Clinical and Diagnostic Research. 2017; 11: QD08–QD10.